HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Osman O. Al-Radi Vivek Rao Terrence Yau Richard D. Weisel Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Al-Radi, O. O. Articles by Weisel, R. D. Search for Related Content PubMed PubMed Citation Articles by Al-Radi, O. O. Articles by Weisel, R. D. Related Collections Pericardium

Ann Thorac Surg 2003;75:S674-S677
© 2003 The Society of Thoracic Surgeons

---

I: Pathophysiology of ischemic-reperfusion injury

Cardiac cell transplantation: closer to bedside

^a Division of Cardiac Surgery, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada

* Address reprint requests to Vivek Rao, MD, PhD, 200 Elizabeth St, 14-222, Toronto, ON, Canada.
e-mail: vivek.rao{at}uhn.on.ca

Presented at the 3^rd International Symposium on Myocardial Protection From Surgical Ischemic-Reperfusion Injury, Asheville, NC, June 2–6, 2002.

Abstract

The current treatment for heart failure is inadequate for a large number of patients who do not qualify for heart transplantation or innovative surgical therapy. Cellular augmentation of damaged myocardium has been actively investigated in the past decade. Cells best suited for the task are skeletal myoblasts and bone morrow mesenchymal stem cells. Both cell types are autologous, abundant, and easy to harvest. The focus of early human trials will be to establish the safety of an effective cellular dose. Trials conducted with an inadequate cellular dose may discredit cell therapy because of lack of effect but, more importantly, may provide a false sense of safety because of a lack of adverse events secondary to a small inoculating dose.

This article has been cited by other articles:

				R. P. Gallegos and R. M. Bolman III Stem Cell Induced Regeneration of Myocardium Card. Surg. Adult, January 1, 2008; 3(2008): 1657 - 1668. [Full Text]

				V. Rao Stem cell transplantation for ischemic cardiomyopathy: Hope or hype? J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1492 - 1493. [Full Text] [PDF]

				A. N. Patel, L. Geffner, R. F. Vina, J. Saslavsky, H. C. Urschel Jr, R. Kormos, and F. Benetti Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1631 - 1638. [Abstract] [Full Text] [PDF]

				S. Fazel, G. H.L. Tang, D. Angoulvant, M. Cimini, R. D. Weisel, R.-K. Li, and T. M. Yau Current Status of Cellular Therapy for Ischemic Heart Disease Ann. Thorac. Surg., June 1, 2005; 79(6): S2238 - S2247. [Abstract] [Full Text] [PDF]

				L. Barandon, T. Couffinhal, P. Dufourcq, P. Alzieu, D. Daret, C. Deville, and C. Duplaa Repair of Myocardial Infarction by Epicardial Deposition of Bone Marrow Cell-Coated Muscle Patch in a Murine Model Ann. Thorac. Surg., October 1, 2004; 78(4): 1409 - 1417. [Abstract] [Full Text] [PDF]

				L. Barandon Editorial comment: Cellular cardiomyoplasty: 'inject is easy, demonstrate is complicated' Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 350 - 351. [Full Text] [PDF]

				Y.-F. Xiao, J.-Y. Min, and J. P. Morgan Immunosuppression and xenotransplantation of cells for cardiac repair Ann. Thorac. Surg., February 1, 2004; 77(2): 737 - 744. [Abstract] [Full Text] [PDF]

				J. F. Heubach, E. M. Graf, J. Leutheuser, M. Bock, B. Balana, I. Zahanich, T. Christ, S. Boxberger, E. Wettwer, and U. Ravens Electrophysiological properties of human mesenchymal stem cells J. Physiol., February 1, 2004; 554(3): 659 - 672. [Abstract] [Full Text] [PDF]